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Background/Aims: The controlled attenuation parameter 
(CAP) implemented in FibroScan® is reported to be a non-
invasive means of detecting steatosis (>10% steatosis). 
We aimed to evaluate the usefulness of CAP in detecting 
steatosis among health checkup examinees and to assess 
its correlation with ultrasonography (US). Methods: Consecu-
tive CAP results were retrospectively collected. A total of 280 
subjects were included. Results: Fatty liver was detected 
in 119 subjects (42.5%) by US, whereas it was detected in 
160 subjects (57.1%) by the CAP. The numbers of subjects 
with S0:S1:S2:S3 steatosis according to the CAP value were 
120:59:58:43, respectively. The mean CAP values were 
203.34±28.39 dB/m for S0, 248.83±6.14 dB/m for S1, 
274.33±8.53 dB/m for S2, and 322.35±22.20 dB/m for 
S3. CAP values were correlated with body weight (r=0.404, 
p<0.001), body mass index (r=0.445, p<0.001), and the 
fatty liver grade by US (r=0.472, p<0.001). Among the 161 
subjects with normal US findings, steatosis was detected in 
65 subjects (40.4%) using the CAP. Conclusions: The CAP 
seems to be useful for detecting very low-grade hepatic 
steatosis in health checkup examinees. Its role in predicting 
subjects with a risk of metabolic derangement needs to be 
evaluated. (Gut Liver 2015;9:405-410)
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a component of 
the metabolic syndrome which consists of insulin resistance, 
visceral obesity, dyslipidemia, hypertension and diabetes mel-
litus.1 It is the most prevalent chronic liver disease worldwide, 
ranging from simple steatosis to steatohepatitis, where the pres-
ence and the severity of inflammation and fibrosis are impor-
tant prognostic factors pertaining liver associated mortality.2-4 
On the other hands, hepatic steatosis may suggest subclinical 
metabolic risk factors such as cardiovascular changes5 and may 
accelerate the progression of the co-existing liver diseases.6
Hepatic steatosis is accumulation of triglycerides and other 
fats within the hepatocytes reflecting impairment of normal 
processes of synthesis and elimination of fat. The diagnosis of 
hepatic steatosis can be made when fat in the liver exceeds 5% 
by weight.7 The current gold standard for evaluating steatsosis 
is liver biopsy, although its invasiveness limits its value as a 
screening tool especially in general population.8,9 Instead, the 
most practically used noninvasive means of detecting steatosis 
has been ultrasonography (US), although it can only detect ste-
atosis of greater than 30%.10 Recently, controlled attenuation 
parameter (CAP) being implemented on FibroScan® (Echosens, 
Paris, France) has been introduced in order to evaluate both ste-
atosis and fibrosis simultaneously.11 It is a noninvasive means of 
quantitatively evaluating steatosis, and is reported to be highly 
sensitive in detecting low grade steatosis as fat deposition >10% 
can be identified.12 In addition, CAP values may not be influ-
enced by liver fibrosis and can be operated by a person without 
any US imaging skills without significant interoperator vari-
ability.13 Several recent studies reported that CAP is significantly 
correlated with the quantity of steatosis in patients with chronic 
liver diseases.12,14,15 However, not many studies investigated its 
role as a screening tool in general population. Although there 
may be debates as for the need of steatosis screening, a pro-
portion of the population might benefit from the screening by 
identifying risk factors associated with metabolic derangements 
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such as diabetes mellitus and cardiovascular abnormalities. The 
aim of this study is to evaluate the usefulness of CAP in detect-
ing steatosis among health checkup examinees and to assess its 
correlation with US.
MATERIALS AND METHODS
1. Subjects
From January 2013, 280 subjects who had CAP measured 
during health checkup program at Gangnam Severance Hos-
pital, Seoul, Korea, were consecutively enrolled for this study. 
Other data including demographics, blood test results, liver 
stiffness measurement (LSM) and findings of abdominal US 
from database of Health Checkup Center were collected retro-
spectively. All subjects were examined between 8 and 11 AM 
after a 12-hour overnight fast. The study protocol was reviewed 
by Institutional Review Board of Gangnam Severance Hospital 
(number: 3-2014-0141). Conforming to the ethical guidelines of 
the 1975 Declaration of Helsinki, this study was approved by an 
ethics committee and granted an exemption. 
2. Blood samples
Serological parameters included fasting glucose, aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT), 
γ-glutamyltranspeptidase, total bilirubin, platelet count, pro-
thrombin time, total cholesterol, high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cholesterol and tri-
glycerides. Blood test was performed on the same day of CAP 
measurement. 
3. Body composition
Anthropometry and body composition were measured with 
an X-scan plus II (Jawon Medical Co., Ltd., Kyungsan, Korea). 
Anthropometric and body fat indices has been identified to be 
useful in showing body fat distribution and to have correlations 
with metabolic parameters.16-18 Weight (kg) and height (cm) were 
measured to the nearest 0.1 kg and 0.1 cm, respectively. Bio-
electrical impedance analysis was done for body composition 
via tetra-polar electrode method using eight touch electrodes. 
Mass of body fat, lean body mass, body mass index (BMI), per-
cent body fat, waist to hip ratio, segmental analysis (lean body 
mass of arms, legs, and trunk), and basal metabolic rate were 
assessed. 
4. Ultrasonography
Ultrasound scanning was performed by two professional 
radiologists using a 5-mHz transducer. Radiologists were not 
aware of the subjects’ clinical details or laboratory findings. 
The criterion for fatty change of liver was hyperechogenic liver 
tissue with fine, tightly packed echoes.19 With the 5-mHz trans-
ducer posterior beam penetration was an inevitable finding. The 
degree of fatty change was assessed by the fall in echo ampli-
tude with depth (rate of posterior beam attenuation), increasing 
discrepancy of echo amplitude between liver and kidney, and 
loss of echoes from the walls of the portal veins. Mild fatty liver 
was defined by a slight increase in liver echogenicity, a slight 
exaggeration of liver and kidney echo discrepancy, and relative 
preservation of echoes from the walls of the portal vein. Moder-
ate fatty liver was accompanied by loss of echoes from the walls 
of the portal veins, particularly from the peripheral branches, 
resulting in a featureless appearance of the liver. In addition, 
greater posterior beam attenuation was found and a greater 
discrepancy between hepatic and renal echoes. Severe fatty liver 
was recognized by a greater reduction in beam penetration, loss 
of echoes from most of the portal vein wall, including the main 
branches, and a large discrepancy between hepatic and renal 
echoes.
5. CAP measurement and liver stiffness
CAP was performed by a trained operator following the 
manufacturer’s instruction. CAP assessment was on a Fibroscan 
501® (Echosens, Paris, France) with the tip of M probe placing 
on the skin between the ribs over the right lobe of the liver. 
The CAP and liver stiffness were measured on the right lobe of 
the liver through the intercostal space. Ultrasound attenuation 
is only calculated when the LSM was valid in order to ensure 
an accurate attenuation value of the liver, and an attempt was 
made to collect ≥10 valid LSMs. A success rate of ≥60% and 
the ratio of the interquartile range (IQR) of liver stiffness to the 
median (IQR/MLSM) ≤30% were considered reliable and used for 
the final analysis. As our working definition, steatosis grade was 
decided by cutoffs of CAP according to a previous report by 
Sasso et al.11; 238 dB/m for S ≥1, 260 dB/m for S ≥2, and 293 
dB/m for S3. 
6. Statistical analysis
Continuous variables are expressed as mean±standard de-
viation. Categorical variables were expressed as counts and 
percent. Correlations among the variables were analyzed using 
Spearman correlation coefficient. The Student t-test was per-
formed to compare variables between the groups. All statistical 
analyses were performed using the SPSS version 13.0 (SPSS 
Inc., Chicago, IL, USA). All statistical tests were two-sided and 
were evaluated at the 0.05 level of significance.
RESULTS
1. Baseline characteristics
The baseline characteristics of the subjects and the results of 
measured parameters are listed in Table 1. The mean age was 
51 years and 56.1% of the subjects were male. The mean values 
of CAP and LSM were 245.9±47.9 dB/m, and 4.6±2.8 kPa. The 
mean values of AST and ALT were 24.9±12.0 and 27.4±25.0 IU/
L. The mean values of fasting glucose and total cholesterol were 
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100.9±16.0 mg/dL and 200.3±37.7 mg/dL. All the other mean 
values of blood chemistry were within normal ranges. Only a 
small number of subjects had diabetes (6.7%), hepatitis B (4.6%) 
or C (0.4%) infection.
2. Prevalence of steatosis
US identified fatty liver in 119 subjects (42.5%), while CAP 
measurement revealed S1-3 grade steatosis in 160 subjects 
(57.1%). By US, 65 subjects (54.6%) had mild fatty liver, 44 
subjects (37.0%) had moderate fatty liver, and 10 subjects (8.4%) 
had severe fatty liver. By CAP value, subjects with S1, S2, and 
S3 grade steatosis were 59 (36.9%), 58 (36.2%) and 43 (26.9%), 
respectively. The mean values of CAP in S0, S1, S2, and S3 
groups were 203.3±28.4 dB/m, 248.8±6.1 dB/m, 274.3±8.5 dB/
m, and 322.4±22.2 dB/m, respectively (Table 2). Distribution of 
CAP was plotted by the degree of fatty change in US (Fig. 1). 
3. Correlations with CAP
CAP was significantly correlated with parameters as shown 
in Table 3. BMI, systolic blood pressure (BP), fasting glucose, 
Table 1. Baseline Characteristics of Subjects (n=280)
Characteristic Value
Clinical
   Age, yr
   Male sex
   DM
   Systolic BP, mm Hg
   Diastolic BP, mm Hg
   CAP, dB/m
   Stiffness, kPa
   HBsAg positive
   Anti-HCV positive
Anthropometric
   BMI, kg/m2
   Body fat rate, %
   Visceral fat grade, 1-24
   Visceral fat area, cm2
   Visceral fat, kg
   Subcutaneous fat, kg
Biochemical
   AST, IU/L
   ALT, IU/L
   GGT, IU/L
   Fasting glucose, mg/dL
   Total cholesterol, mg/dL
   Triglyceride, mg/dL
   HDL, mg/dL
   LDL, mg/dL
51±11
157 (56.1)
18 (6.7)
124.29±14.67
77.7±9.75
245.91±47.86
4.59±2.84
13 (4.6)
1 (0.4)
23.90±3.03
25.73±5.46
10.19±3.37
94.81±41.02
2.33±1.75
14.54±3.80
24.91±12.02
27.43±24.98
37.80±56.71
100.89±15.97
200.26±37.68
121.15±72.69
51.34±12.90
121.69±31.65
Data are presented as mean±SD or number (%).
DM, diabetes mellitus; BP, blood pressure; CAP, controlled attenua-
tion parameter; HBsAg, hepatitis B surface antigen; HCV, hepatitis C 
virus; BMI, body mass index; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; GGT, γ-glutamyltranspeptidase; HDL, high-
density lipoprotein; LDL, low-density lipoprotein. 
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Fig. 1. Scatterplot and regression line showing a positive correlation 
between the grade of fatty change (0, normal; 1, mild; 2, moderate; 
and 3, severe) detected by ultrasonography and the controlled attenu-
ation parameter in the checkup subjects.
Table 2. Fatty Change Noted by Ultrasonography and the Controlled 
Attenuation Parameter
Characteristic No. (%) Mean±SD, dB/m
Fatty change by US (n=119)
   Mild fatty liver
   Moderate fatty liver
   Severe fatty liver
Fatty change by CAP (n=160), dB/m 
   S1 (238 to <260)
   S2 (260 to <293)
   S3 (≥293)
65 (54.6)
44 (37.0)
10 (8.4)
59 (36.9)
58 (36.2)
43 (26.9)
-
-
-
248.83±6.14
274.33±8.53
322.35±22.20
US, ultrasonography; CAP, controlled attenuation parameter.
Table 3. Correlation between the Controlled Attenuation Parameter 
and Clinical Parameters
Parameter Correlation (r) p-value
US finding (fatty liver grade)
BMI
Visceral fat grade
Systolic BP
Fasting glucose
Triglyceride
HDL
LDL
0.472
0.445
0.421
0.223
0.229
0.269
-0.155
0.182
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.012
0.003
US, ultrasonography; BMI, body mass index; BP, blood pressure; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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triglyceride, LDL, and grade of fatty liver by US showed signifi-
cant positive correlations with CAP value. HDL level showed a 
negative significant correlation with CAP value. 
4. Characteristics of subjects whose steatosis was detected 
only by CAP value 
Among 161 subjects whose liver echogenicity was normal 
in US, steatosis was detected in 65 subjects (65/161, 40.4%) by 
CAP value, and most of them (53.8%) had S1 grade CAP value. 
None of patients whose liver steatosis was detected by US had 
normal values on CAP evaluation. We compared clinical pa-
rameters between US-CAP concordant subjects (normal liver 
echogenicity in US and S0 grade of CAP value) and US-CAP 
discordant subjects (normal liver echogenicity in US but ste-
atosis by CAP value). Subjects whose steatosis was recognized 
by CAP had significantly higher BMI, body fat rate, visceral fat 
grade, systolic BP, triglyceride, LDL, and low HDL than subjects 
without steatosis that was confirmed by the both tools, US and 
CAP measurements (Table 4). However, mean values of diastolic 
BP, fasting glucose, total cholesterol, AST, and ALT were not 
different statistically.
DISCUSSION
In our study, liver steatosis, evaluated by CAP was well cor-
related with clinical parameters that were associated with meta-
bolic derangements. In addition, CAP measurement was useful 
in identifying the low grade steatosis that was not conspicuous 
on US, and thus might be useful in early detection of metabolic 
derangements in health checkup examinees. 
The need for steatosis screening in general population is still 
under controversy. However, health checkup is often provided 
for persons that do not possess overt, serious health problems 
in order to prevent disease by recognizing subtle signs jeopar-
dizing healthy condition, and several studies suggest hepatic 
steatosis as an early predictor of cardiovascular and metabolic 
derangements.20,21 NAFLD has been suggested as an indicator of 
preclinical insulin resistance even in nonobese individuals, and 
some investigators even recommended young NAFLD patients 
to undergo oral glucose tolerance test in order to predict the 
risk of type 2 diabetes.21-23 Furthermore, NAFLD is reported to 
suggest subclinical cardiovascular changes such as increased 
arterial stiffness and carotid arterial wall thickness.5,24-26 There-
fore, early detection of NAFLD might contribute in predicting 
and preventing serious and prevalent metabolic diseases such 
as type 2 diabetes or cardiovascular disease. In accordance with 
these findings, our results also showed that the presence of he-
patic steatosis by CAP correlated with variables suggestive of 
poor metabolic condition. Fortunately, simple hepatic steatosis 
without inflammation and fibrosis is a reversible condition 
which can be normalized after lifestyle modification including 
diet and/or physical activity intervention.27,28 It would be inter-
esting to investigate whether alleviated hepatic steatosis would 
reduce the metabolic risks, and such studies would be able to 
determine the usefulness of steatosis screening. 
Currently, US is recognized as the most useful and widely ac-
cepted noninvasive technique for the detection of liver steatosis. 
However, US has its pitfalls as its results tend to be operator 
dependent and its grading system is somewhat subjective.29 In 
addition, quantification of fatty change is limited as it is de-
scribed in only four categories: normal, mild, moderate, and 
severe. Some investigators even report relatively low sensitivity 
of US in identifying existence of fatty liver.30,31 Therefore, in 
comparison with the histological studies, some review articles 
raise questions on the diagnostic ability and reliability of US in 
detecting fatty liver.32,33 On the other hands, CAP measures and 
Table 4. Clinical Implication of Fatty Change Not Detected by Ultrasonography but Detected by the Controlled Attenuation Parameter 
Parameter Normal liver by US and CAP (n=96) Fatty liver not by US but by CAP (n=65) p-value
BMI, kg/m2
Body fat rate, %
Visceral fat grade
Systolic BP, mm Hg
Diastolic BP, mm Hg
Fasting glucose, mg/dL
Total cholesterol, mg/dL
AST, IU/L
ALT, IU/L
Triglyceride, mg/dL
HDL, mg/dL
LDL, mg/dL
22.03±2.61
24.21±5.37
7.88±3.43
119.5±12.79
74.51±8.79
95.99±10.85
192.46±35.83
23.78±13.87
22.71±30.34
89.17±44.15
55.31±12.42
114.95±33.17
23.73±1.45
26.24±5.64
10.51±2.55
124.42±15.85
76.63±9.95
95.85±12.22
200.63±37.39
21.37±5.78
20.60±10.46
106.48±49.66
50.92±10.54
126.02±28.63
<0.001
0.022
<0.001
0.032
0.156
0.641
0.165
0.187
0.131
0.022
0.021
0.030
US, ultrasonography; CAP, controlled attenuation parameter; BMI, body mass index; BP, blood pressure; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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describes hepatic steatosis in a numeric scale, which may pro-
duce more objective results. The numeric scales are often useful 
when the examinees want to compare their hepatic fatty values 
over time after serial measurements. CAP seems to be able to 
produce objective assessment of hepatic steatosis, along with 
noninvasively measured liver fibrosis, and it is operator inde-
pendent as well as easily accessible. CAP may be a noninvasive 
and practical means of detecting hepatic steatosis in patients as 
well as in general population. However, until now, there is no 
consensus on cutoff values regarding steatosis grade. In addi-
tion, there are no validated indices that describe the reliability 
of CAP values. For liver stiffness, IQR/M is known to be a factor 
of reliability. However, in a previous report comparing histology 
and CAP, IQR/M of CAP was not an independent predictor of 
discordance between steatosis grade and CAP.34 Further study 
is warranted to decide optimal cutoff value for detecting early 
fatty changes and to identify means of assessing the reliability 
of the CAP study.
Our study reports the correlation coefficient of 0.472 between 
findings of US and those of the CAP study and it should be 
pointed out that the level of correlation is not so strong. Unfor-
tunately reports on the correlation between results from US and 
that of CAP are lacking, and more studies on this matter are 
needed as indicated in a recent review article.35 
This study has several limitations. First, comparison with the 
histologic grade was not included. To be conducted with data 
from health checkup, invasive confirmation with biopsy was 
unrealistic and even unethical. Second, cause of hepatic ste-
atosis was not clearly depicted. As these are real life data and 
almost every man has social drinking, alcoholic or nonalcoholic 
causes could not be easily discriminated. Third, we could not 
show the relation between CAP and insulin resistance since se-
rum insulin level was not included in health checkup item.
In conclusion, among health checkup examinees, CAP seems 
to be useful in detecting hepatic steatosis to predict metabolic 
derangement. Even with normal US findings, those subjects 
whose hepatic steatosis could be diagnosed by CAP had worse 
metabolic parameters compared with those that were free of 
fatty liver after both US and CAP studies. Histologic validation 
is warranted to set cutoffs of CAP for steatosis grade in subjects 
without other definite causes of the chronic liver diseases.
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